BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36572885)

  • 1. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
    Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
    World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression and CD8
    Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
    Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 4. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
    Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
    Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
    Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
    J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenomic Landscape of Neuroendocrine Prostate Cancer.
    Bhinder B; Ferguson A; Sigouros M; Uppal M; Elsaeed AG; Bareja R; Alnajar H; Eng KW; Conteduca V; Sboner A; Mosquera JM; Elemento O; Beltran H
    Clin Cancer Res; 2023 Aug; 29(15):2933-2943. PubMed ID: 37223924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
    Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
    Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of neuroendocrine prostate cancer.
    Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
    Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of neuroendocrine prostate cancer.
    de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
    Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
    Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
    Wang HT; Yao YH; Li BG; Tang Y; Chang JW; Zhang J
    J Clin Oncol; 2014 Oct; 32(30):3383-90. PubMed ID: 25225419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
    Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
    Front Oncol; 2020; 10():571308. PubMed ID: 33598420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
    Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA
    Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.